Azenta Q3 EPS Beats by 45%, Revenue Jumps 12%; Guides FY26 Revenue Above $613M
AZTA sits 88% above its 52-week low of $15.93.
Summary
Azenta delivered a strong Q3, with adjusted EPS of $0.16 beating consensus by 45% and revenue up 12% year-over-year. Growth was driven by Sample Management Solutions and Multiomics, though gross margin dipped due to fixed-cost absorption and quality remediation in Automated Stores. The company also repurchased $50M in shares under its existing buyback program. FY26 guidance calls for revenue of $613M-$618M and adjusted EBITDA of $59M-$62M, providing a clear outlook after the Q2 goodwill impairment and B Medical Systems sale. This follows the Q2 net loss of $160.8M and the $63M B Medical divestiture, marking a turnaround quarter. The stock trades at 52x forward earnings, reflecting high expectations that this beat may reinforce.
Updates
· SEC 10-Q — The 10-Q reports Q3 net income of $2.5M, nine-month net loss of $173.8M, and completion of the B Medical Systems sale on July 1, 2026 for $63.0M.
At the time of this announcement, AZTA was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $15.93 to $41.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.